AU Patent

AU2016203837A1 — 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as Btk- inhibitors

Assigned to Merck Sharp and Dohme BV · Expires 2016-06-30 · 10y expired

What this patent protects

4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS The present invention relates to 6-5 membered fused pyridine ring compounds according to formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions…

USPTO Abstract

4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS The present invention relates to 6-5 membered fused pyridine ring compounds according to formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to formula I in the treatment of Brutons Tyrosine Kinase (Btk) mediated disorders.

Drugs covered by this patent

Patent Metadata

Patent number
AU2016203837A1
Jurisdiction
AU
Classification
—
Expires
2016-06-30
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.